Skip to main content
Log in

Requirement of monocytes and T-helper cells during development of tumor cell cytotoxicity in targeted T cells

  • Original Articles
  • Placental Alkaline Phosphatase, Immunoconjugate, T Cell Lysis, Cytotoxicity
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

In cocultures of human plancental alkaline phosphatase(PLAP)-positive MO4 tumor cells and human peripheral blood mononuclear cells (PBMC), also containing a heteroconjugate (7E8-OKT3) synthesized between the anti-PLAP monoclonal antibody 7E8 and the anti-CD3 antibody OKT3, and supplemented with low levels of recombinant interleukin-2 (rIL-2), T cells are progressively activated, resulting in tumor cell lysis. To unravel the contribution of PBMC subsets to the generation of this targetable cytotoxicity, PBMC subsets were studied after their isolation by cell sorting, either from fresh PBMC or from PBMC peractivated with OKTe3 and rIL-2. Whereas no targetable cytotoxicity was found in Fc-receptor-bearing CD3-cells, tumor cells were lysed by CD3+ T cells (mostly CD8+) isolated from pre-activated PBMC. When isolated from fresh PBMC, neither the CD8+ T cell subset, nor the total CD3+ T cell population developed significant targetable cytotoxicity, even in the presence of rIL-2. Thus, additional cell types are essential for the CD8+ T cell activation. Indeed. CD4+ T cells isolated from pre-activated but not from fresh PBMC were capable of eliciting cytotoxicity in fresh CD8+ T cells. The non-targeted monocytes were found to be the activators of the CD4+ T cells. In summary, targeting T cells to the surface of a tumor cell is not sufficientper se to achieve activation and lysis. The progressive tumor cell lysis by targeted T cells seems to be initiated by non-targeted monocytes activating CD4+ T cells, these cells in turn promoting CD8+ T cell activation, necessary for the development of cytotoxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Barr IG, Miescher S, Fliedner V von, Buchegger F, Barras C, Lanzavecchia A, Mach J-P, Carrel S (1989) In vivo localization of a bispecific antibody which targets human T lymphocytes to lyse human colon-cancer cells. Int J Cancer 43:501

    PubMed  Google Scholar 

  2. Bolhuis RLH, Lamers CHJ, Goey SH, Eggermont AMM, Trimbos JBMZ, Stoter G, Lanzavecchia A, Di Re E, Miotti S, Raspagliesli E, Rivolitini L, Colnaghi MI (1992) Adoptive immunotherapy of ovarian carcinoma with Bs-MAb-targeted lymphocytes: a multicenter study. Int J Cancer Suppl 7:78

    PubMed  Google Scholar 

  3. Borst J, Griend RJ van de, Oostveen JW van, Ang S-W, Melief CJ, Seidman JG, Bis RLH (1987) A T cell receptor γ/CD3 complex found on cloned functional lymphocytes. Nature 325:683

    PubMed  Google Scholar 

  4. Brissinck J, Demanet C, Moser M, Leo O, Thielemans K (1991) Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. J Immunol 147:4019

    PubMed  Google Scholar 

  5. Britton KE (1990) The development of new radiopharmaceuticals Eur J Nucl Med 16:373

    PubMed  Google Scholar 

  6. Byers VS, Baldwin RW (1991) Rationale for clinical use of immunotoxin in cancer and autoimmune disease. Semin Cell Biol 2:59

    PubMed  Google Scholar 

  7. Cherwinski HM, Schumacher JH, Brown KD, Mosmann TR (1987) Two types of mouse helper T cell clone. III. Further diffrences in lymphokin synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays and monoclonal antibodies. J Exp Med 166:1229

    PubMed  Google Scholar 

  8. Demanet C, Brissinck J, Van Mechelen M, Leo O, Thielemans K (1991) Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype × anti-CD3). J Immunol 147:1091

    PubMed  Google Scholar 

  9. Epstein AL, Khawli LA (1991) Tumor biology and monoclonal antibodies: overview of basic principles and clinical considerations. Antibody Immunoconjugates Radiopharm 4:373

    Google Scholar 

  10. Ferrini S, Progione I, Mammoliti S, Colnaghi MI, Menard S Moretta A, Moretta L (1989) Re-targeting of human lymphocytes expressing the T cell receptor gamma/delta to ovarian carcinoma cells by the use of bispecific monoclonal antibodInt. J Cancer 44:245

    Google Scholar 

  11. Garrido MA, Perez P, Titus JA, Valdayo MJ, Winkler DF, Barbieri SA, Wunderlich JR, Segal DM (1990) Targeted cytotoxic cells in human peripheral blood lymphocytes. J Immunol 44:2891

    Google Scholar 

  12. Reference deleted

  13. Hendrix PG, Hoylaerts MF, Nouwen EJ, De Broe ME (1990) Enzyme immunoassay of human placental and germ-cell alkaline phosphatase in serum. Clin Chem 36:1793

    PubMed  Google Scholar 

  14. Herlyn D, Koprowski H (1982) IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci USA 79:4761

    PubMed  Google Scholar 

  15. Hoogenboom HR, Raus JC, Volckaert G (1991) Targeting of tumor necrosis factor to tumor cells: secretion by myeloma cells of a genetically engineered antibody-tumor necrosis factor hybrid molecule. Biochim Biophys Acta 1096:345

    PubMed  Google Scholar 

  16. Ite JP, Janeway CA (1984) Cloned helper T cells can kill B lymphoma cells in the presence of specific antigen: Ia restriction and cognate vs noncognate interactions in cytolysis. Eur J Immunol 14:878

    PubMed  Google Scholar 

  17. Kim JA, Woods A, Becker-Dunn E, Bottomly K (1985) Distinct functional phenotypes of cloned Ia-restricted helper T cells. J Exp Med 162:188

    PubMed  Google Scholar 

  18. Kipps TJ, Farham P, Punt J, Herzenberg L (1985) Importance of immunoglobulin isotype in human antibody-dependent cell-mediated cytotoxicity directed by murine moncolonal antibodies. J Exp Med 161:1

    PubMed  Google Scholar 

  19. Lanzavecchia A, Scheidegger D (1987) The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol 17:105

    PubMed  Google Scholar 

  20. Larson SM (1990) Clinical radioimmunodetection, 1978–1988: overview and suggestions for standardization of clinical trials. Cancer Res 50 [Suppl 3]:892

    Google Scholar 

  21. Mazzocchi A, Anichini A, Castelli C, Sensi M, Poli F, Russo C, Parmiani G (1990) T lymphocytes can mediate lysis of autologous melanoma cells by multiple mechanisms: evidence with a single T cell clone. Cancer Immunol Immunother 32:13

    PubMed  Google Scholar 

  22. Nitta T, Sato K, Yagita H, Okumura K, Ishü S (1990) Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335:368

    PubMed  Google Scholar 

  23. Oldham RK (1991) Custom-tailored drug immunoconjugates in cancer therapy. Mol Biother 3:148

    PubMed  Google Scholar 

  24. Perez P, Titus JA, Lotze MT, Cuttitta F, Longo DL, Groves ES, Rabin H, Durda PJ, Segal DM (1986) Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to antitumor antibody. J Immunol 137:2069

    PubMed  Google Scholar 

  25. Qian J, Titus JA, Andrew SM, Mezzanzanica D, Garrido MA, Wunderlich JR, Segal DM (1991) Human PBL targeted with bispecific antibodies release, cytokines that are essential for inhibiting tumor growth. J Immunol 146:3250

    PubMed  Google Scholar 

  26. Shih LB, Xuan H, Sharkey RM, Goldenberg DM, (1990) A fluorouridine-anti-CEA immunoconjugate is therapeutically effective in a human colonic cancer xenograft model. Int J Cancer 15:1101

    Google Scholar 

  27. Smans KA, Hoylaerts MF, Hendrickx HF, Goergen MJ, De Broe ME (1991) Tumor cell lysis by in-situ activated human peripheralblood mononuclear cells. Int J Cancer 47:431

    PubMed  Google Scholar 

  28. Stevensen GT, Glennie MJ (1980) Surface immunoglobulin of B-lymphocytic tumors as a therapeutic agent. Cancer Surv 4:213

    Google Scholar 

  29. Van Dijk J, Warnaar SO, Van Eendenburg JDH, Thienpont M, Braakman E, Boot JHA, Flueren FJ, Bolhuis RLH (1989) Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen. Int J Cancer 43:344

    PubMed  Google Scholar 

  30. Van Wauwe JP, De Mey JR, Goossens JG (1980) OKT3: a monoclonal anti-human T-lymphocyte antibody with potent mitogenic properties. J Immunol 124:2708

    PubMed  Google Scholar 

  31. Wawrzynczak EJ (1991) Systemic immunotoxin therapy of cancer: advances and prospects. Br J Cancer 64:624

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smans, K.A., Hoylaerts, M.F. & De Broe, M.E. Requirement of monocytes and T-helper cells during development of tumor cell cytotoxicity in targeted T cells. Cancer Immunol Immunother 38, 43–52 (1994). https://doi.org/10.1007/BF01517169

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01517169

Key words

Navigation